


## BIP-135

<b>Cat. No.:</b>	HY-111055		
<b>CAS No.:</b>	941575-71-9		
<b>Molecular Formula:</b>	C <sub>21</sub> H <sub>13</sub> BrN <sub>2</sub> O <sub>3</sub>		
<b>Molecular Weight:</b>	421.24		
<b>Target:</b>	GSK-3		
<b>Pathway:</b>	PI3K/Akt/mTOR; Stem Cell/Wnt		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### BIOLOGICAL ACTIVITY

<b>Description</b>	BIP-135 is a potent and selective ATP-competitive GSK-3 inhibitor, with IC <sub>50</sub> s of 16 nM and 21 nM for GSK-3α and GSK-3β, respectively. BIP 135 exhibits neuroprotective effect <sup>[1]</sup> .										
<b>IC<sub>50</sub> &amp; Target</b>	GSK-3α 16 nM (IC <sub>50</sub> )	GSK-3β 21 nM (IC <sub>50</sub> )									
<b>In Vitro</b>	<p>BIP-135 (20-30 μM; 72 hours) increases the survival motor neuron (SMN) protein levels at a dose of 25 μM in human SMA fibroblasts. And the typical bell-shaped dose-response curve is observed due to some toxicity at higher concentrations<sup>[1]</sup>. BIP-135 (20 μM; 48 hours) is a superior neuroprotective agent in the model of oxidative stress<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Western Blot Analysis<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>Human SMA fibroblasts</td> </tr> <tr> <td>Concentration:</td> <td>20 μM, 25 μM, 30 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>72 hours</td> </tr> <tr> <td>Result:</td> <td>Led to a 7-fold increase in SMN levels at 25 μM.</td> </tr> </table>			Cell Line:	Human SMA fibroblasts	Concentration:	20 μM, 25 μM, 30 μM	Incubation Time:	72 hours	Result:	Led to a 7-fold increase in SMN levels at 25 μM.
Cell Line:	Human SMA fibroblasts										
Concentration:	20 μM, 25 μM, 30 μM										
Incubation Time:	72 hours										
Result:	Led to a 7-fold increase in SMN levels at 25 μM.										
<b>In Vivo</b>	<p>BIP-135 does not appear to be toxic and was well-tolerated by the animals (no decrease in body weight)<sup>[1]</sup>. BIP-135 (75 mg/kg; i.p.; daily; from postnatal day 0 to 21) prolongs the median survival time of Δ7 SMA KO mouse model of spinal muscular atrophy<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Male and female SMN2<sup>+/+</sup>, SMN2Δ7<sup>+/+</sup>, Smn<sup>+/-</sup> mice<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>75 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection; daily; from postnatal day 0 to 21</td> </tr> <tr> <td>Result:</td> <td>Caused a modest extension in the median survival of SMA KO animals by two days.</td> </tr> </table>			Animal Model:	Male and female SMN2 <sup>+/+</sup> , SMN2Δ7 <sup>+/+</sup> , Smn <sup>+/-</sup> mice <sup>[1]</sup>	Dosage:	75 mg/kg	Administration:	Intraperitoneal injection; daily; from postnatal day 0 to 21	Result:	Caused a modest extension in the median survival of SMA KO animals by two days.
Animal Model:	Male and female SMN2 <sup>+/+</sup> , SMN2Δ7 <sup>+/+</sup> , Smn <sup>+/-</sup> mice <sup>[1]</sup>										
Dosage:	75 mg/kg										
Administration:	Intraperitoneal injection; daily; from postnatal day 0 to 21										
Result:	Caused a modest extension in the median survival of SMA KO animals by two days.										

---

## REFERENCES

[1]. Chen PC, et al. Identification of a Maleimide-Based Glycogen Synthase Kinase-3 (GSK-3) Inhibitor, BIP-135, that Prolongs the Median Survival Time of  $\Delta 7$  SMA KO Mouse Model of Spinal Muscular Atrophy. ACS Chem Neurosci. 2012 Jan 18;3(1):5-11.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA